View Financial HealthEntheon Biomedical 배당 및 자사주 매입배당 기준 점검 0/6Entheon Biomedical 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-36.1%자사주 매입 수익률총 주주 수익률-36.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 23Entheon Biomedical Corp. (CNSX:ENBI) signed a letter of intent to acquire Entheon Biomedical Corp. for CAD 5.33 million in a reverse merger transaction.Nutravisor Inc. signed a letter of intent to acquire Entheon Biomedical Corp. (CNSX:ENBI) for CAD 5.33 million in a reverse merger transaction on December 18, 2025. Under the terms of the LOI, Entheon has agreed to issue an aggregate of 53,333,333 shares of Entheon to existing shareholders of Nutravisor at a per share price equal to CAD 0.75 for aggregate consideration equal to approximately CAD 40 million on a post-consolidation basis. Entheon shall be required to complete an approximately 6.93:1 share consolidation such that the value allocated to Entheon shareholders shall be CAD 1.5 million. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor. Following the transaction, Nutravisor's existing management team will assume leadership of the Resulting Issuer. All but one of the directors of Entheon shall resign and the board of directors will be comprised of directors nominated by Nutravisor. Entheon is expected to change its name concurrent with closing, subject to regulatory approval. The Definitive Agreement is expected to be executed in January, 2026. The LOI contains customary deal protection provisions, including a mutual break fee in the amount of CAD 0.04 million payable if the Proposed Transaction is terminated by either party under certain specific circumstances. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. The transaction is expected to close on or before March 30, 2026, subject to satisfactory tax, corporate and securities law advice for both Entheon and Nutravisor and will be set forth in a definitive agreement to be entered into among the parties, Execution of the Definitive Agreement, Completion of satisfactory due diligence, Receipt of all required regulatory, corporate, and shareholder approvals, Acceptance of the Proposed Transaction by the Canadian Securities Exchange, Receipt of approval for the listing of the common shares of the Resulting Issuer by the CSE, Completion of the Concurrent Offering, Delivery of financial statements of both Entheon and Nutravisor; and No material adverse changes in either party.공시 • Oct 14Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025.공시 • Apr 08Entheon Biomedical Corp. Announces Board ChangesEntheon Biomedical Corp. appointed Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of Fire & Flower, one of Canada's first retail focused cannabis companies, where he led its early growth and served as Director of Business Development. Shortly thereafter, he helped take the first EV company public in Canada, Taiga Motors, where he served as a strategic advisor. Mr. Newlands also co-founded Hoshi International, a producer of medicinal cannabis with a state of the art facility in Portugal, focusing on the emerging European market. Harrison also co-founded Hypercharge Networks, Canada's first publicly traded EV charging company. Harrison was formerly a partner at Rockbank Capital, a Vancouver based merchant bank, and has been a managing partner at North King Capital over the past 4 years, where he continues to advise both public and private companies, as well as invest. Andrew Hegle has resigned from the Company's Board of Directors.공시 • Jan 07Entheon Biomedical Corp. announced that it has received CAD 0.5 million in fundingOn January 6, 2025. Entheon Biomedical Corp. closed the transaction.공시 • Dec 03Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in fundingEntheon Biomedical Corp. announced a non-brokered private placement of 30,000,000 units at a price of CAD 0.1 per unit for gross proceeds of CAD 3,000,000 on December 2, 2024. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant exercisable for one additional share at an exercise price of CAD 0.15 per share for a period of 24 months from the date of issuance. All securities to be issued will be subject to a four-month and a day hold period. The Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.공시 • Oct 15Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024. Location: vancouver Canada공시 • Apr 20Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in fundingOn April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug. 19, 2024.공시 • Apr 12Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in fundingEntheon Biomedical Corp. announced a private placement of up to 2,950,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 147,500 on April 11, 2024. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of CAD 0.10 per share for a period of 60 months from the date of issuance. All securities issued under the placement will be subject to a four-month and one-day hold period. The company may pay finder’s fees in accordance with the policies of the Canadian Securities Exchange.공시 • Oct 31Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023. Location: Vancouver Vancouver Canada공시 • Aug 01Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science OfficerEntheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.공시 • Feb 18Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023.공시 • Jan 07Entheon Biomedical Corp. Announces CFO ChangesEntheon Biomedical Corp. announced the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ENTB.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ENTB.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Entheon Biomedical 배당 수익률 vs 시장ENTB.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ENTB.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (ENTB.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ENTB.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ENTB.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ENTB.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ENTB.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/17 10:54종가2025/12/18 00:00수익2025/08/31연간 수익2024/11/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Entheon Biomedical Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 23Entheon Biomedical Corp. (CNSX:ENBI) signed a letter of intent to acquire Entheon Biomedical Corp. for CAD 5.33 million in a reverse merger transaction.Nutravisor Inc. signed a letter of intent to acquire Entheon Biomedical Corp. (CNSX:ENBI) for CAD 5.33 million in a reverse merger transaction on December 18, 2025. Under the terms of the LOI, Entheon has agreed to issue an aggregate of 53,333,333 shares of Entheon to existing shareholders of Nutravisor at a per share price equal to CAD 0.75 for aggregate consideration equal to approximately CAD 40 million on a post-consolidation basis. Entheon shall be required to complete an approximately 6.93:1 share consolidation such that the value allocated to Entheon shareholders shall be CAD 1.5 million. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor. Following the transaction, Nutravisor's existing management team will assume leadership of the Resulting Issuer. All but one of the directors of Entheon shall resign and the board of directors will be comprised of directors nominated by Nutravisor. Entheon is expected to change its name concurrent with closing, subject to regulatory approval. The Definitive Agreement is expected to be executed in January, 2026. The LOI contains customary deal protection provisions, including a mutual break fee in the amount of CAD 0.04 million payable if the Proposed Transaction is terminated by either party under certain specific circumstances. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. The transaction is expected to close on or before March 30, 2026, subject to satisfactory tax, corporate and securities law advice for both Entheon and Nutravisor and will be set forth in a definitive agreement to be entered into among the parties, Execution of the Definitive Agreement, Completion of satisfactory due diligence, Receipt of all required regulatory, corporate, and shareholder approvals, Acceptance of the Proposed Transaction by the Canadian Securities Exchange, Receipt of approval for the listing of the common shares of the Resulting Issuer by the CSE, Completion of the Concurrent Offering, Delivery of financial statements of both Entheon and Nutravisor; and No material adverse changes in either party.
공시 • Oct 14Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025.
공시 • Apr 08Entheon Biomedical Corp. Announces Board ChangesEntheon Biomedical Corp. appointed Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of Fire & Flower, one of Canada's first retail focused cannabis companies, where he led its early growth and served as Director of Business Development. Shortly thereafter, he helped take the first EV company public in Canada, Taiga Motors, where he served as a strategic advisor. Mr. Newlands also co-founded Hoshi International, a producer of medicinal cannabis with a state of the art facility in Portugal, focusing on the emerging European market. Harrison also co-founded Hypercharge Networks, Canada's first publicly traded EV charging company. Harrison was formerly a partner at Rockbank Capital, a Vancouver based merchant bank, and has been a managing partner at North King Capital over the past 4 years, where he continues to advise both public and private companies, as well as invest. Andrew Hegle has resigned from the Company's Board of Directors.
공시 • Jan 07Entheon Biomedical Corp. announced that it has received CAD 0.5 million in fundingOn January 6, 2025. Entheon Biomedical Corp. closed the transaction.
공시 • Dec 03Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in fundingEntheon Biomedical Corp. announced a non-brokered private placement of 30,000,000 units at a price of CAD 0.1 per unit for gross proceeds of CAD 3,000,000 on December 2, 2024. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant exercisable for one additional share at an exercise price of CAD 0.15 per share for a period of 24 months from the date of issuance. All securities to be issued will be subject to a four-month and a day hold period. The Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.
공시 • Oct 15Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024. Location: vancouver Canada
공시 • Apr 20Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in fundingOn April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug. 19, 2024.
공시 • Apr 12Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in fundingEntheon Biomedical Corp. announced a private placement of up to 2,950,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 147,500 on April 11, 2024. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of CAD 0.10 per share for a period of 60 months from the date of issuance. All securities issued under the placement will be subject to a four-month and one-day hold period. The company may pay finder’s fees in accordance with the policies of the Canadian Securities Exchange.
공시 • Oct 31Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023. Location: Vancouver Vancouver Canada
공시 • Aug 01Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science OfficerEntheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.
공시 • Feb 18Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023.
공시 • Jan 07Entheon Biomedical Corp. Announces CFO ChangesEntheon Biomedical Corp. announced the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer.